Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.62 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.60 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.60 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | HTR2C | P28335 | 2/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30760618 | 1.00 | ADRA2C (0.62) | ADRA2CPLOD2PLOD3PLOD1KDM4E | |
| Hydrochloric Acid SCHEMBL16209753 | 0.98 | ADRA2C (0.60) | ADRA2CPLOD2PLOD3PLOD1KDM4E | |
| Hydrochloric Acid SCHEMBL30760605 | 0.98 | ADRA2C (0.60) | ADRA2CPLOD2PLOD3PLOD1KDM4E | |
| SCHEMBL1286697 | 0.87 | PLOD2 (0.60) | ADRA2CPLOD2PLOD3PLOD1KDM4E | |
| SCHEMBL3319386 | 0.87 | ALDH1A1 (0.73) | ADRA2CPLOD2PLOD3PLOD1KDM4E | |
| SCHEMBL29631156 | 0.87 | ALDH1A1 (0.73) | ADRA2CPLOD2PLOD3PLOD1KDM4E | |
| SCHEMBL3320233 | 0.85 | PLOD2 (0.59) | ADRA2CPLOD2PLOD3PLOD1KDM4E | |
| SCHEMBL3728008 | 0.85 | AOC3 (0.57) | KDM4EALDH1A1HSD17B10PARP1TP53BP1 | |
| SCHEMBL10739904 | 0.84 | PLOD2 (0.66) | ADRA2CPLOD2PLOD3PLOD1KDM4E | |
| SCHEMBL18352938 | 0.84 | PLOD2 (0.62) | ADRA2CPLOD2PLOD3PLOD1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190834-B1 | PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2011-03-02 | — | — | EP | claimed |
| EP-2190834-A1 | PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER | F. Hoffmann-Roche AG (CH) | 2010-06-02 | — | — | EP | claimed |
| EP-2065380-A1 | Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer | F.HOFFMANN-LA ROCHE AG (CH) | 2009-06-03 | — | — | EP | claimed |
| WO-2009024332-A1 | PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-26 | — | — | WO | claimed |
| EP-1919875-A2 | PYRAZOLE DERIVATIVES AND THEIR USE AS PKA AND PKB MODULATORS | Astex Therapeutics Limited (GB) | 2008-05-14 | — | — | EP | claimed |
| WO-2006136829-A2 | PYRAZOLE DERIVATIVES AND THEIR USE AS PKA AND PKB MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | claimed |
| EP-0946539-B1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-13 | — | — | EP | claimed |
| US-20030069233-A1 | Sulphonamide derivatives, process for their preparation, and their use as medicaments | SMITHKLINE BEECHAM P.L.C. | 2003-04-10 | — | — | US | claimed |
| EP-0946539-A1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1999-10-06 | — | — | EP | claimed |
| WO-1998027081-A1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1998-06-25 | — | — | WO | claimed |
| EP-4317162-B1 | 1,3-BENZODIOXOLANE-CONTAINING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | XIAN XINTONG PHARMACEUTICAL RES CO LTD (CN) | 2026-02-04 | — | — | EP | disclosed |
| US-20240059694-A1 | COMPOUND CONTAINING 1,3-BENZODIOXOL STRUCTURE AND PREPARATION METHOD AND USE THEREOF | XI'AN XINTONG PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2024-02-22 | — | — | US | disclosed |
| EP-4317162-A1 | 1,3-BENZODIOXOLANE-CONTAINING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Xi'An Xintong Pharmaceutical Research Co., Ltd. (CN) | 2024-02-07 | — | — | EP | disclosed |
| CN-117396462-A | Antiviral compounds | 英菲克斯治疗有限公司 | 2024-01-12 | — | — | CN | disclosed |
| WO-2022206531-A1 | 1,3-BENZODIOXOLANE-CONTAINING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 西安新通药物研究股份有限公司 | 2022-10-06 | — | — | WO | disclosed |
| US-20030069233-A1 | Sulphonamide derivatives, process for their preparation, and their use as medicaments | SMITHKLINE BEECHAM P.L.C. | 2003-04-10 | — | — | US | disclosed |
| US-6423717-B1 | NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-23 | — | — | US | disclosed |
| CN-1246116-A | Sulfonamide derivatives, process for their preparation and their use as medicaments | SMITHKLINE BEECHAM PLC (GB) | 2000-03-01 | — | — | CN | disclosed |
| EP-0946539-A1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998027081-A1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1998-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069233-A1 | Sulphonamide derivatives, process for their preparation, and their use as medicaments | TPMT, MPST, STS | ADRA2C 3512/4885PLOD2 4652/4885PLOD3 4851/4885 |
| US-20240059694-A1 | COMPOUND CONTAINING 1,3-BENZODIOXOL STRUCTURE AND PREPARATION METHOD AND USE THEREOF | BTK, JAK3, JAK1 | ADRA2C 2796/4885PLOD2 2611/4885PLOD3 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.